{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-035699","form_type":"8-K","ticker":"ADGM","cik":"0002006986","company_name":"Adagio Medical Holdings, Inc.","filed_at":"2026-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.975039+00:00","generated_at":"2026-05-15T08:43:09.714261+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Adagio Medical reports FY2025 net loss $25.1M; FULCRUM-VT trial fully enrolled with 97% acute effectiveness","bullets":["Net loss of $25.1M for FY2025, down from $75.0M in FY2024; Q4 net loss $3.3M vs $57.4M.","Completed enrollment of 209-patient FULCRUM-VT pivotal IDE trial; preliminary 97% acute effectiveness.","Closed private placement with gross proceeds up to $50M; upfront $19M to fund FDA submission.","Cash and equivalents $17.1M as of Dec 31, 2025; no revenue reported.","Appointed former Medtronic executive Sean Salmon to Board; added senior sales and manufacturing VPs."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-035699","json":"https://secwatch.observer/filing/0001104659-26-035699.json","markdown":"https://secwatch.observer/filing/0001104659-26-035699.md","text":"https://secwatch.observer/filing/0001104659-26-035699.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2006986/000110465926035699/0001104659-26-035699-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2006986/000110465926035699/adgm-20260326x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:43:09.714261+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}